Select a medication above to begin.
Tice BCG
BCG live intravesical
Black Box Warnings .
Biohazard
contains live, attenuated mycobacteria; prepare, handle, and dispose of as biohazard material due to potential transmission risk; BCG infections reported in health care workers, primarily from accidental needle stick or exposure to skin lacerations during BCG preparation
Serious Infection Risk
nosocomial infections reported in immunosuppressed pts receiving parenteral drugs prepared in same areas as BCG; BCG capable of dissemination when admin. by intravesical route; serious infections, incl. fatal, reported in pts receiving intravesical BCG
Adult Dosing .
Dosage forms: SUSP
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments
bladder CA in situ
- [50 mg intravesically qmo x6-12mo]
- Start: 50 mg intravesically qwk x6wk; Info: for prophylaxis and tx; may repeat start dose x1
papillary bladder tumor prophylaxis, stage Ta and/or T1
- [50 mg intravesically qmo x6-12mo]
- Start: 50 mg intravesically qwk x6wk
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.